

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| (51) International Patent Classification <sup>6</sup> :<br>C12Q 1/00, 1/02, 1/68, G01N 21/75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |  | A1                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (11) International Publication Number: WO 95/33070              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | (43) International Publication Date: 7 December 1995 (07.12.95) |
| (21) International Application Number: PCT/US95/06696<br>(22) International Filing Date: 25 May 1995 (25.05.95)<br>(30) Priority Data:<br>08/249,394                      26 May 1994 (26.05.94)                      US<br>(71) Applicant: NEW YORK MEDICAL COLLEGE [US/US];<br>Valhalla, NY 10595 (US).<br>(72) Inventors: DARZYNKIEWICZ, Zbigniew, D.; 37 Meadow<br>Lane, Chappaqua, NY 10514 (US). LI, Xun; 1653<br>Morningview Drive, Yorktown Heights, NY 10598 (US).<br>TRAGANOS, Frank, N.; 301 66th Street, New York, NY<br>10021 (US). MELAMED, Myron, R.; 35 Braeside Lane,<br>Dobbs Ferry, NY 10522 (US).<br>(74) Agent: JACKSON, Auzville, Jr.; 8652 Rio Grande Road,<br>Richmond, VA 23229 (US). |  | (81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ,<br>EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT,<br>LU, LV, MD, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK,<br>TJ, TT, UA, UG, UZ, VN, European patent (AT, BE, CH,<br>DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE),<br>OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR,<br>NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).<br><br>Published<br><i>With international search report.</i> |                                                                 |
| (54) Title: DETECTION OF HALOGENATED PRECURSORS INCORPORATED INTO DNA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |
| (57) Abstract                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |
| <p>A method for detecting halogenated precursors incorporated into DNA is presented. The method is based on the selective photolysis of DNA by ultraviolet light at the sites of an incorporated halogenated precursor, such as the thymidine base analogs 5-bromo-2-deoxyuridine, 5-iodo-2-deoxyuridine, 5-fluoro-2-deoxyuridine or 5-chloro-2-deoxyuridine. The 3'-hydroxyl termini of the DNA single strand breaks may be marked with a fluorescent label. The labelled DNA may be analyzed by flow cytometry or fluorescence microscopy.</p>                                                                                                                                                               |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                 |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

**DETECTION OF HALOGENATED PRECURSORS INCORPORATED INTO DNA**

5

**BACKGROUND OF THE INVENTION****Field of the Invention**

The present invention relates to the detection of DNA  
10 replication and DNA repair, and more particularly to the  
detection of halogenated precursors incorporated into the DNA.

**Description of the Related Art**

The process of DNA replication is studied primarily to  
15 assess the proliferative potential of cell populations and to  
study progression of the cell cycle. The study of cell  
proliferation has application in the prognosis of tumors and  
predictions of the likelihood of organ transplant rejection. In  
the process of DNA repair, DNA damage is detected and corrected;  
20 this process is studied mostly to evaluate the genotoxicity,  
i.e., mutagenicity and/or carcinogenicity, of environmental  
toxins and other substances.

There are two distinct methodologies currently used to  
analyze DNA replication or repair. One method is based on the  
25 incorporation of a radioactive DNA precursor, such as tritiated  
thymidine, into the repaired DNA molecules followed by

autoradiographic detection or quantitation using a scintillation counter. This method is being phased out due to the ecological disadvantages associated with radioactive tracers and the cumbersome analysis of cells required by the autoradiography  
5 procedure.

The second method utilizes fluorescence rather than radioactivity. Most assays of this type are based on the detection of incorporated halogenated precursors, such as the thymidine base analogs 5-bromo-2-deoxyuridine (BrdUrd) or 5-iodo-  
10 2-deoxyuridine (IdUrd) (1,2). These assays are widely used in research laboratories and clinics. Their clinical usefulness is primarily in the evaluation of tumor prognosis; numerous observations indicate that the proportion of cells replicating DNA, or the potential doubling time of proliferating cells, has  
15 strong prognostic value (3-6).

BrdUrd is substituted stoichiometrically for thymidine in DNA molecules during the S-phase (synthesis phase) of the cell cycle. During the S-phase the cellular DNA content is doubling between the G<sub>1</sub> and G<sub>2</sub> cell phases (gap phases). The amount of  
20 incorporated BrdUrd is related to the new DNA content, i.e., the S-phase of the cell cycle.

The most common method of BrdUrd detection is based on the use of anti-BrdUrd antibodies (1,2). This conventional method, though proven to be of great value in numerous instances, has a  
25 serious drawback in that it requires DNA denaturation, i.e., strand separation, prior to incubation with the BrdUrd-specific

antibody. This step is necessary to make the epitope, i.e., the incorporated precursor, accessible and reactive with the antibody. Denaturation involves either heat ( $\geq 90^{\circ}\text{C}$ ) or acid (2-4 M HCl) treatment. Under these conditions many cellular proteins undergo denaturation and/or extraction. The requirement for DNA denaturation makes it very difficult to combine the BrdUrd incorporation assay with other probes of cell phenotype or function, such as surface immunofluorescence, or the detection of intracellular antigens or other proteins. Furthermore, because of the differences in chromatin structure between different cell types, which in turn affect the DNA denaturation step, the BrdUrd antibody method fails when used in some clinical samples, or cell lines. Several approaches designed to bypass the denaturation step, such as the partial digestion of DNA with nucleases, appear to be of limited practical value (7).

Alternative methods employing BrdUrd, based on the quenching of fluorochromes such as Hoechst 33258 (8) or acridine orange (9) by incorporated BrdUrd, are less sensitive compared to the assay which utilizes BrdUrd-specific antibody. Dye quenching methods have been used to detect cells that incorporated BrdUrd during continuous exposure to the precursor (10) but, because of their low sensitivity, have limited application, especially in the clinic.

The publications cited herein are incorporated by reference into this disclosure and appear in an Appendix to the application.

**SUMMARY OF THE INVENTION**

Accordingly, it is an object of the present invention to provide a method of detecting a halogenated precursor incorporated into DNA molecules under non-denaturing conditions as a measurement of DNA replication or DNA repair.

It is another object of the present invention to provide a sensitive method of detecting a halogenated precursor incorporated into DNA molecules as a measurement of DNA replication or DNA repair.

It is yet another object of the present invention to provide a method of detecting a halogenated precursor incorporated into DNA molecules which may be used in conjunction with, and without adversely affecting, other probes of cell phenotype or function.

It is a further object of the present invention to provide a method of detecting a halogenated precursor incorporated into DNA molecules which may be used in conjunction with, and without adversely affecting, methods of detecting intracellular antigens and other proteins.

It is yet a further object of the present invention to provide a method of detecting a halogenated precursor incorporated into DNA which may be used to simultaneously detect cells undergoing apoptosis, i.e., programmed cell death.

A still further object of the present invention to provide a method of detecting DNA replication which may be used as a tool to aid in the prognosis of tumors.

A final object of the present invention is to provide a method of detecting DNA repair as a tool for evaluating the genotoxicity, i.e., mutagenicity and/or carcinogenicity, of environmental toxins and other substances.

5       The invention is a method of detecting DNA replication or DNA repair through detection of halogenated precursors incorporated into DNA. The halogenated precursor is a thymidine base analog such as 5-bromo-2-deoxyuridine (BrdUrd), 5-iodo-2-deoxyuridine (IdUrd), 5-fluoro-2-deoxyuridine (FdUrd), or 5-  
10 chloro-2-deoxyuridine (CldUrd).

The preferred method comprises incorporating a halogenated precursor into DNA within cells; exposing the cells to ultraviolet (UV) light to induce photolysis of the DNA within the cells at the sites of precursor incorporation; fixing the cells;  
15 marking the photolysis-generated termini of the DNA with a fluorescent label using an exogenous enzyme to catalyze the labeling reaction; and detecting the fluorescence of the fluorescent-labeled DNA. The fluorescence may be detected *in situ* by flow cytometry or fluorescence microscopy, and is used to  
20 determine the amount of newly synthesized DNA in the cells and, thus, the current phase of the cell cycle. First, the amount of incorporated halogenated precursor is determined from the amount of fluorescence. Second, the amount of newly synthesized DNA within the cells is determined from the amount of incorporated  
25 halogenated precursor. Finally, the current phase of the cell cycle is determined from the amount of newly synthesized DNA.

These determinations are accomplished using conventional methods well known to an ordinary person skilled in the art.


Another method comprises incorporating a halogenated precursor into DNA within biological entities, such as cells, bacteria, and viruses; exposing the biological entities to ultraviolet light to induce photolysis of the DNA within the biological entities at the sites of precursor incorporation; isolating the DNA from the biological entities; analyzing the isolated DNA; marking the photolysis-generated termini of the analyzed DNA with a fluorescent label; and detecting the fluorescence of the fluorescent-labeled DNA.

The present invention does not require denaturation of the DNA molecules since it is based upon fluorescent labeling of DNA single strand breaks at the sites of precursor incorporation which are induced by exposure to ultraviolet light, i.e., photolysis. This feature of the invention is a great advantage in that it allows the method to be used in conjunction with, and without adversely affecting, other probes of cell phenotype or function, and methods for detecting intracellular antigens and other proteins. In addition, the method can be used to simultaneously detect cells undergoing apoptosis, i.e., programmed cell death.

The above and numerous other objects of the invention that may be achieved by the preferred embodiment of the invention will



be more readily understood from the following detailed description.



#### DESCRIPTION OF THE PREFERRED EMBODIMENT

A method for detecting a halogenated precursor incorporated into DNA as a measurement of DNA replication or DNA repair without denaturation of the DNA molecules is presented. The method may be used with cells in suspension, thin tissue sections, bacteria, and viruses. Examples of cells for which the method has been used include human leukemic HL-60 and MOLT 4 cell lines, normal human lymphocytes stimulated in vitro by the mitogen phytohemagglutinin, human leukemic bone marrow cells, and human breast carcinoma tissue.

This method may be employed to detect DNA replication in the analysis of cell proliferation. The most extensive application is expected to be in clinical oncology, where cell proliferation assays are used as prognostic markers of tumors. The method may also be used in monitoring tumor treatment efficiency, in cases in which the tumor can be sampled by venipuncture or bone marrow

aspiration or biopsy (hematopoietic diseases) or by needle biopsy (solid tumors), for example, during treatment. In addition, the method may be employed to predict the likelihood of organ transplant rejection, i.e., to test for proliferation of the recipient's lymphocytes in the presence of specific donor cells.

The method does not require denaturation of the DNA molecules since it is based upon fluorescent labeling of DNA single strand breaks at the sites of precursor incorporation which are induced by exposure to ultraviolet light, i.e., photolysis. This feature allows the method to be used in conjunction with, and without adversely affecting, other probes of cell phenotype or function, and methods for detecting intracellular antigens and other proteins. In addition, the method can be used to simultaneously detect cells undergoing apoptosis, i.e., programmed cell death.

The method may also be used to detect DNA repair. Because several fluorescent labels may be attached at each DNA single strand break, i.e., at each site of incorporated precursor, the method is theoretically several times more sensitive than the conventional method based on the use of anti-BrdUrd antibodies. High sensitivity favors its use in tests of the mutagenicity of drugs, food components and additives, and environmental toxins, as a measurement of DNA repair replication.

The preferred method comprises incorporating a halogenated precursor into DNA within cells; exposing the cells to ultraviolet (UV) light to induce photolysis of the DNA within the

cells at the sites of precursor incorporation; fixing the cells; marking the photolysis-generated termini of the DNA with a fluorescent label using an exogenous enzyme to catalyze the labeling reaction; and detecting the fluorescence of the fluorescent-labeled DNA. The fluorescence may be detected *in situ* by flow cytometry or fluorescence microscopy, and is used to determine the amount of newly synthesized DNA in the cells and, thus, the current phase of the cell cycle. First, the amount of incorporated halogenated precursor is determined from the amount of fluorescence. Second, the amount of newly synthesized DNA within the cells is determined from the amount of incorporated halogenated precursor. Finally, the current phase of the cell cycle is determined from the amount of newly synthesized DNA. These determinations are accomplished using conventional methods well known to an ordinary person skilled in the art.

The cells were exposed *in vitro* or *in vivo* to a halogenated precursor such as the thymidine base analogs 5-bromo-2-deoxyuridine (BrdUrd), 5-iodo-2-deoxyuridine (IdUrd), 5-fluoro-2-deoxyuridine (FdUrd), or 5-chloro-2-deoxyuridine (CldUrd), to effect the incorporation of the precursor into the DNA within the cells. *In vivo* exposure was accomplished by conventional intravenous, intramuscular, or intravesicular addition; these methods of incorporation are well known to an ordinary person skilled in the art. *In vitro* exposure was accomplished by incubation of the cells with the halogenated precursor. The cells were incubated with concentrations of precursor ranging

from about 10  $\mu$ M to about 50  $\mu$ M, depending upon the type and physical state of the cells. Optimum incorporation into suspended cells was usually achieved with the lower concentrations of precursor, such as 10, 20, or 30  $\mu$ M, whereas  
5 optimum incorporation into tissue sections usually required higher concentrations, such as 30, 40 or 50  $\mu$ M. However, all five concentrations, i.e., 10, 20, 30, 40, and 50  $\mu$ M, may be used for both suspended cells and tissue sections. The incubation periods ranged from about five minutes to about eight hours,  
10 again depending upon the type and physical state of the cells. Optimum incorporation into suspended cells was usually achieved with shorter incubation periods, such as five, thirty, or forty minutes, whereas optimum incorporation into tissue sections was usually achieved with longer incubation periods, such as one or  
15 two hours. The incubations were carried out at about 37°C in the dark.

DNA in which a halogenated deoxynucleotide such as BrdUrd or IdUrd is substituted for thymidine is sensitive to illumination with UV light: absorption of high energy photons by such labeled  
20 DNA results in its photolysis or breakage (11, 12). Photons of approximately 310 nm wavelength are especially effective in causing DNA single strand breaks at sites of BrdUrd incorporation (11). Uniform illumination of DNA is expected to generate DNA single strand breaks in proportion to the amount of incorporated  
25 halogenated deoxynucleotide. It is believed that similar results will be obtained with DNA in which FdUrd or CldUrd is substituted

for thymidine. It is also believed that incorporation studies involving FdUrd may provide an indirect indication of the sensitivity of various tumors to 5-fluorouracil (5-FU), the most widely used antitumor agent for the treatment of solid tumors.

- 5 The method of the present invention may provide an accurate and sensitive technique for the detection of 5-FU in tumor cells. In addition, incorporation studies with FdUrd may provide insight into the mechanism of action of 5-FU.

It was determined that illumination of the cell suspension  
10 in Petri dishes or tissue sections on slides placed face down and positioned directly on the glass surface of a Foto UV Analytical DNA transilluminator (Fotodyne, Inc., New Berlin, WI) containing four 15 watt 300 nm bulbs and illuminated for approximately five minutes, was optimal in terms of induction of DNA single strand  
15 breaks in BrdUrd-labeled cells or tissue sections. An illumination period of approximately ten minutes was determined to be optimal for IdUrd-labeled cells. It is believed that similar results will be obtained with DNA in which FdUrd or CldUrd is substituted for thymidine.

- 20 Two variations of the preferred method exist with respect to the step for marking the 3'-hydroxyl termini of the photolysis-generated DNA strand breaks with a fluorochrome. Both direct and indirect marking procedures may be employed. In one embodiment, the DNA termini are directly labeled with a deoxynucleotide  
25 conjugated with a fluorochrome, such as fluorescein-conjugated deoxyuridine triphosphate (fluorescein-12-dUTP). In a second

embodiment, the DNA termini were labeled with a deoxynucleotide conjugated with a first agent, such as biotinylated deoxyuridine triphosphate (b-dUTP) or digoxigenin-conjugated deoxyuridine triphosphate (d-dUTP), and thereafter incubated with a second  
5 agent conjugated with a fluorochrome, such as avidin-fluorescein isothiocyanate or fluorescein-conjugated anti-digoxigenin antibody, respectively, which binds to the first agent of the conjugated deoxynucleotide. An exogenous enzyme such as terminal deoxynucleotidyl transferase or DNA polymerase (nick translation  
10 system) is used to catalyze the labeling reaction in both variations.

Another method comprises incorporating a halogenated precursor into DNA within biological entities, such as cells, bacteria, and viruses; exposing the biological entities to  
15 ultraviolet light to induce photolysis of the DNA within the biological entities at the sites of precursor incorporation; isolating the DNA from the biological entities; analyzing the isolated DNA; marking the photolysis-generated termini of the analyzed DNA with a fluorescent label; and detecting the  
20 fluorescence of the fluorescent-labeled DNA. The incorporation step is accomplished by exposing the biological entities *in vitro* to the halogenated precursor, which is a thymidine base analog such as BrdUrd, IdUrd, FdUrd, or CldUrd. *In vitro* exposure is accomplished by incubation of the biological entities with the  
25 precursor. Isolation of the DNA from the biological entities is accomplished using conventional methods, such as extraction,

which are well known to an ordinary person skilled in the art. Analysis of the isolated DNA is accomplished by conventional methods such as gel electrophoresis and blotting assays, which are well known to an ordinary person skilled in the art. The  
5 photolysis-generated termini of the analyzed DNA are marked with a fluorescent label using the methods described herein or using conventional methods well known to an ordinary person skilled in the art. The fluorescence of the fluorescent-labeled DNA is  
10 detected using methods well known to an ordinary person skilled in the art.

The following examples will serve to illustrate the present invention but are in no way intended to limit the scope of the invention which is defined in the appended claims. The materials and methods presented in the examples are cited in previous  
15 publications (13, 14).

#### EXAMPLE 1

*Cells.* Human leukemic HL-60 cell lines were maintained in RPMI 1640 medium (Gibco BRL Life Technologies, Inc., Grand  
20 Island, NY) supplemented with ten percent fetal calf serum, 100 units/ml penicillin, 100 ug/ml streptomycin and 2mM L-glutamine. The cells were split every third day and were diluted 1:2 one day before each experiment. Cell densities in cultures did not exceed  $5 \times 10^5$  cells/ml.

*Precursor Incorporation.* The cells were incubated with 10  $\mu$ M BrdUrd (Sigma Chemical Co., St. Louis, MO) at 37°C in the dark for one hour.

5 *Photolysis.* At the end of the incubation period, the cells were illuminated with ultraviolet (UV) light of 310 nm wavelength for five minutes.

*Cell Fixation.* The cells were rinsed in phosphate buffered saline (PBS) and fixed in 70% ethanol. In some experiments, the cells were also fixed in 1% formaldehyde (pH 7.4) at 0-4°C for 15  
10 minutes, and then post-fixed and stored in 70% ethanol.

*Fluorochrome Labeling.* The 3'-hydroxyl termini of the DNA single strand breaks generated by photolysis were labeled with digoxigenin-conjugated deoxyuridine triphosphate (d-dUTP) followed by incubation with an fluorochrome-conjugated anti-  
15 digoxigenin antibody. This was accomplished using the commercial kit for DNA strand break labeling developed to identify apoptotic cells (ApoptTag™ kit, ONCOR Inc., Gaithersburg, MD), according to the protocol included with the kit by the vendor.

*Flow Cytometry.* The cells were rinsed in PBS with 0.1% Triton-X 100 and resuspended in 1 ml of PBS containing 5  $\mu$ g/ml of  
20 propidium iodide (PI) and 0.1% RNase A (both from Sigma Chemical Company). Flow cytometry was performed on a FACScan Flow Cytometer (Becton Dickinson, San Jose, CA). The red (PI) and green (fluorescein) fluorescence emissions from each cell were  
25 separated and measured using the standard optics of the FACScan. The data from  $10^4$  cells per sample were collected, stored, and



analyzed using LYSIS II software (Bectin-Dickinson). The signals of green fluorescence were measured using both linear and logarithmic amplification for each sample.

#### EXAMPLE 2

5 Human leukemic HL-60 cells were cultured as in Example 1. The cells were incubated with 10  $\mu$ M IdUrd (Sigma Chemical Co., St. Louis, MO) at 37°C in the dark for one hour. The cells were photolysed for ten minutes and fixed as before. The 3'-hydroxyl termini of the DNA strand breaks generated by photolysis were  
10 labeled with d-dUTP as before. Fluorescence of individual cells was measured by flow cytometry as before.

#### EXAMPLE 3

Human leukemic HL-60 cells were cultured, incubated with 10  $\mu$ M BrdUrd, photolysed, and fixed as in Example 1. The 3'-  
15 hydroxyl termini of the DNA single strand breaks generated by photolysis were labeled directly with fluorochrome-conjugated dUTP (fluorescein-12-dUTP) (Boehringer Mannheim Biochemicals, Indianapolis, IN). Fluorescence of individual cells was measured by flow cytometry as before.

#### EXAMPLE 4

20 Human leukemic HL-60 cells are cultured, labeled with 10  $\mu$ M BrdUrd, photolysed, and fixed as described in Example 1.

Fluorochrome Labeling. The 3'-hydroxyl termini of the DNA single strand breaks generated by photolysis are labeled with  
25 biotinylated dUTP (b-dUTP) followed by incubation with fluorochrome-coupled avidin. Two procedures are followed, each

using a different exogenous enzyme to catalyze the addition of dUTP to the DNA termini:

- (1) *TdT Assay*. After fixation and washing, cells are resuspended in 50 ul of a solution containing 0.1 M sodium cacodylate (pH 7.0) (Sigma), 1 mM  $\text{CoCl}_2$  (Sigma), 0.1mM dithiothreitol (Sigma), 0.05 mg/ml bovine serum albumin (Sigma), 10 units of terminal deoxynucleotidyl transferase (Boehringer Mannheim), and 0.5 nmoles biotin-16-dUTP (TdT buffer). In some experiments, in addition to b-dUTP, unlabeled dATP, dGTP, and dCTP are included, each at a concentration of 20 uM. The cells are incubated in this solution at 37° C, for time intervals between 15 minutes and 3 hours, rinsed in PBS, and resuspended in 100 ul of the staining buffer containing fluoresceinated avidin, which contains 2.5 ug/ml fluoresceinated avidin, 4X saline-sodium citrate buffer (Sigma) (1 x SSC = 0.15 M NaCl, 0.015 M Na-citrate), 0.1% Triton X-100, and 5% (w/v) nonfat dry milk. Cells are incubated with this buffer for 30 minutes at room temperature in the dark. The TdT assay is also performed on cytopsin preparations on slides. The specimens are fixed for 15 minutes in 1% formaldehyde in PBS (pH 7.4), rinsed in PBS, and transferred to 70% ice-cold ethanol for 1 hour. After rinsing in PBS, excess PBS is removed, and 25ul of TdT buffer are pipeted onto slides. The specimens are kept in a humidified chamber for 30 minutes at 37°C. The slides are then rinsed in PBS and incubated in the dark for 30 minutes with the staining buffer. Nucleotides, biotin-16-dUTP, avidin-fluorescein isothiocyanate,

terminal deoxynucleotide transferase, and DNA-polymerase were purchased from Boehringer-Mannheim Biochemicals.

(2) *NT Assay*. Following fixation, the cells are rinsed once with PBS, and  $2 \times 10^5$  cells are suspended in 12.5 ul of nick translation buffer consisting of 2.5  $\text{MgCl}_2$ , 10 mM B-mercaptoethanol (Bio-Rad Laboratories, Richmond, CA), 50 mM Tris (pH 7.8), 10 ug/ml bovine serum albumin, 1 unit *E. coli* DNA polymerase, 0.2 nmoles unlabeled dATP, dGTP, and dCTP, and 0.2 nmoles biotin-16-dUTP. The cells are incubated in nick translation buffer with gentle agitation every 15 minutes, at 15°C, for up to 6 hours. Afterward, the cells are washed in PBS and resuspended in 100 ul of the staining buffer described above.

Fluorescence of individual cells is measured by flow cytometry as before.

15

#### EXAMPLE 5

Human leukemic HL-60 cells are cultured, labeled with 10  $\mu\text{M}$  IdUrd, photolysed, and fixed as described in Example 2 above. The 3'-hydroxyl termini of the DNA single strand breaks generated by photolysis are labeled with biotinylated dUTP (b-dUTP) followed by incubation with fluorochrome-coupled avidin as before. Fluorescence of individual cells is measured by flow cytometry as before.

20

#### EXAMPLE 6

Human breast carcinoma tissue was labeled by incubating thin ( $\leq 1$  mm) slices of freshly resected tumor in RPMI 1640 medium, with 30  $\mu\text{M}$  BrdUrd for one hour at 37°C. The tissue was then

25

fixed overnight in 70% ethanol, embedded in paraffin and sectioned. The sections on slides were deparaffinized and rehydrated. The slides were placed face down on the illuminator and exposed to UV light for five minutes. The 3'-hydroxyl  
5 termini of the DNA single strand breaks generated by photolysis were labeled with d-dUTP, followed by incubation with a fluorochrome-conjugated antibody as in Example 1. Nuclei were counterstained on slides with propidium iodide. In preparations  
10 nuclei fluoresced green while nuclei which had not incorporated the precursor fluoresced red.

#### EXAMPLE 7

Human breast carcinoma tissue is quick frozen in liquid nitrogen, sliced into thin slices, and mounted on a slide, i.e.,  
15 a frozen section is prepared. The tissue is incubated with BrdUrd, photolysed, and fixed as in Example 6. The 3'-hydroxyl termini of the DNA single strand breaks generated by photolysis are labeled with d-dUTP, followed by incubation with a fluorochrome-conjugated antibody as in Example 1. Fluorescence  
20 microscopy is done as in Example 6.

#### EXAMPLE 8

An "imprint" of human breast carcinoma tissue is prepared by making a clean slice through the tumor and pressing the sliced tumor onto a glass slide to leave an imprint of the tumor  
25 consisting of a layer of cells. The slide is incubated with BrdUrd, photolysed, and fixed as in Example 7. The 3'-hydroxyl

termini of the DNA single strand breaks generated by photolysis are labeled with d-dUTP, followed by incubation with a fluorochrome-conjugated antibody as in Example 1. Fluorescence microscopy is done as in Example 6.

5

## EXAMPLE 9

Human breast carcinoma tissue is labeled by incubating thin ( $\leq 1$  mm) slices of freshly resected tumor in RPMI 1640 medium, with 20  $\mu$ M IdUrd for one hour at 37°C. The tissue is then fixed, and sections are prepared, treated and photolysed as in Example 6 above. The 3'-hydroxyl termini of the DNA single strand breaks generated by photolysis are labeled with d-dUTP, followed by incubation with a fluorochrome-conjugated antibody as in Example 1. Fluorescence microscopy is done as in Example 6.

10

## EXAMPLE 10

Human breast carcinoma tissue is labeled with 10  $\mu$ M BrdUrd, fixed and photolysed as described in Example 6 above. The 3'-hydroxyl termini of the DNA single strand breaks generated by photolysis are labeled with biotinylated dUTP (b-dUTP) followed by incubation with fluoresceinated avidin as in Example 4 above. Fluorescence microscopy is done as in Example 6.

15

20

## EXAMPLE 11

Human breast carcinoma tissue is labeled with 20  $\mu$ M IdUrd, fixed and photolysed as described in Example 9 above. The 3'-hydroxyl termini of the DNA single strand breaks generated by photolysis are labeled with biotinylated dUTP (b-dUTP) followed

25

by incubation with fluoresceinated avidin as in Example 4 above. Fluorescence microscopy is done as in Example 6.

- Plots may be made of DNA content versus BrdUrd incorporation in a comparison of the results obtained using the present invention and the conventional immunocytochemical detection method, i.e., the anti-BrdUrd antibody method. Exponentially growing HL-60 cells were incubated in the presence and absence of 50 uM BrdUrd for one hour.
- 10 The incorporated BrdUrd was detected either immunocytochemically, denaturing the DNA with 2.0 M HCl and using the anti-BrdUrd antibody as described elsewhere (17) or using the method of the present invention, without DNA denaturation
- Cellular DNA was counterstained with PI to identify the
- 15 cell cycle position. In both techniques, only the cells with a DNA content equivalent to that of S-phase cells were labeled; the cells that were not incubated with BrdUrd, i.e., control cells, remained unlabeled. The labeling of S-phase cells was very intensive by both assays, as may be noted by the exponential
- 20 scale of the green fluorescence. The results obtained with the method of the present invention were similar to those obtained with the conventional immunocytochemical method.

- Plots may be made of DNA content versus dUTP incorporation for cells following incorporation of either BrdUrd or IdUrd. Cells were incubated with 10 uM BrdUrd or IdUrd for 1 hour, washed, fixed and either

illuminated with UV light

or left

unilluminated.

The samples were then

exposed to d-dUTP in the presence of TdT. Only those cells

exposed to UV light incorporated dUTP into S-phase cells, which

5 could be unambiguously identified in the two-parameter plots.

Similar results were obtained using either BrdUrd or IdUrd.

The advantages of the present invention are numerous.

First, the method does not require denaturation of the DNA

molecules. This feature allows the method to be used in

10 conjunction with, and without adversely affecting, other probes

of cell phenotype or function, and with methods for detecting

intracellular antigens and other proteins. Second, the method is

sensitive. Finally, the method may be used as a tool to aid in

the prognosis of tumors and evaluation of potential genotoxins,

15 i.e., mutagens and/or carcinogens. Many variations will be

apparent to those skilled in the art. It is therefore to be

understood that, within the scope of the appended claims, the

invention may be practiced other than as specifically described.

## APPENDIX

1. Gratzner H.G., Monoclonal antibody to 5-bromodeoxyuridine.  
A new reagent for detection of DNA replication. Science  
5 218: 474-475, 1982.
2. Dolbeare F., Gratzner H.G., Pallavicini M.G., Gray J.W.,  
Flow cytometric measurement of total DNA content and  
incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 80:  
5573-5577, 1983.
- 10 3. Begg A.C., Menally N.J., Shrieve D.C., Karchner H., A  
method to measure the duration of DNA synthesis and the  
potential doubling time from a single sample. Cytometry 6:  
620-626, 1985.
4. Falini B., Canino S., Sacchi S., Ciani C., Martelli M.F.,  
15 Gerdes J., Stein H., Pileri S., Gobbi M., Fagioli M.,  
Minelli O., Flenghi L. Immunocytochemical evaluation of the  
percentage of proliferating cells in pathological bone  
marrow and peripheral blood samples with the Ki-67 and  
anti-bromodeoxyuridine antibodies. Br J Hematol 69: 311-  
20 320, 1988.
5. Williamson K., Halliday I., Hamilton P., Ruddell J., Varma  
M., Maxwell P., Crockard A., Rowland B., In vitro BrdUrd  
incorporation of colorectal tumour tissue. Cell Prolif 26:  
115-124, 1993.



6. deFazio A., Tattersall M.H.N., Rapid fluorometric detection of drug resistant tumor cells. Br J Cancer 52: 633-636, 1985.
7. Takagi S., McFadden M.L., Humphreys R.E., Woda B.A.,  
5 Sairenji T, Detection of 5-bromo-2-deoxyuridine (BrdUrd) incorporation with monoclonal anti-BrdUrd antibody after deoxyribonuclease treatment. Cytometry 14: 640-648, 1993.
8. Latt S.A., Detection of DNA synthesis in interphase nuclei by fluorescence microscopy. J. Cell Biol. 62:546-560,  
10 1974.
9. Darzynkiewicz Z., Traganos F., Melamed M.R., Distinction between 5-bromodeoxyuridine labeled and unlabeled mitotic cells by flow cytometry. Cytometry 3: 345-348, 1983.
10. Poot M., Kubbies M., Hoehn H., Grossman A., Chen Y.,  
15 Rabinovitch P., Cell cycle analysis using continuous bromodeoxyuridine labeling and Hoechst 33258-ethidium bromide bivariate flow cytometry. Meth Cell Biol 33: 185-198, 1990.
11. Hutchinson F., The lesions produced by ultraviolet light in  
20 DNA containing 5-bromouracil. Quart Rev Biophys 6: 201-246, 1973.
12. Zwanenburg T.S.B., van Zeeland A.A., Natarajan A.T.,  
Influence of incorporated bromodeoxyuridine on the  
induction of chromosomal alterations by ionizing radiation  
25 and long wave UV in CHO cells. Mutation Res 150: 283-292, 1985.

13. Gorczyca W., Bruno S., Darzynkiewicz R.J., Gong J.,  
Darzynkiewicz Z., DNA strand breaks occurring during  
apoptosis: their early in situ detection by the terminal  
deoxynucleotidyl transferase and nick translation assays and  
5 prevention by serine protease inhibitors. Int. J Oncol 1:  
639-648, 1992.
14. Gorczyca W., Gong J., Darzynkiewicz Z., Detection of DNA  
strand breaks in individual apoptotic cells by the in situ  
terminal deoxynucleotidyl transferase and nick translation  
10 assays. Cancer Res 52: 1945-1951, 1993.
15. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz  
M.A., Lassota P., Traganos F., Features of apoptotic cells  
measured by flow cytometry. Cytometry 13: 795-808, 1992.
16. Gong J., Traganos F., Darzynkiewicz Z., A selective  
15 procedure for DNA extraction from apoptotic cells  
applicable for gel electrophoresis and flow cytometry. Anal  
Biochem (in press).
17. Li X, Patel R, Melamed M.R., Darzynkiewicz Z., The cell  
cycle effects and induction of apoptosis by 5-bromouridine  
20 in cultures of human leukemic MOLT-4 and HL-60 cell lines  
and mitogen stimulated normal lymphocytes. Cell Prolif (In  
press).

What is claimed as new and desired to be secured by Letters Patent of the United States is:

**Claims**

1. A method for detecting halogenated precursors incorporated into DNA, comprising the steps of:

- (a) incorporating a halogenated precursor into DNA within cells;
- (b) exposing said cells to ultraviolet light to induce photolysis of said DNA within said cells at the sites of said precursor incorporation to generate termini;
- (c) fixing said cells;
- (d) marking the photolysis-generated termini of said DNA within said cells with a fluorescent label;
- (e) detecting the fluorescence of said fluorescent-labeled DNA within said cells;
- (f) determining the amount of said incorporated precursor within said DNA from the amount of said fluorescence;
- (g) determining the amount of newly synthesized DNA in said cells from the amount of said incorporated precursor; and
- (h) determining the phase of the cell cycle from the amount of newly synthesized DNA.

2. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 1, wherein said incorporating step is accomplished by exposing said cells in vitro to said halogenated precursor.

3. A method for detecting halogenated precursors incorporated into DNA, comprising the steps of:

- (a) incorporating a halogenated precursor into

DNA within cells;

(b) Exposing said cells to ultraviolet light to induce photolysis of said DNA within said cells at the sites of said precursor incorporation to generate termini;

(c) fixing said cells;

(d) marking the photolysis-generated termini of said DNA within said cells with a fluorescent label;

(e) detecting the fluorescence of said fluorescent-labeled DNA within said cells; and

(f) determining the amount of said incorporated precursor within said DNA from the amount of said fluorescence.

4. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 1, wherein said halogenated precursor is a thymidine base analog selected from the group consisting of 5-bromo-2-deoxyuridine, 5-iodo-2-deoxyuridine, 5-fluoro-2-deoxyuridine, and 5-chloro-2-deoxyuridine.

5. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 1, wherein said ultraviolet light comprises photons of approximately 310 nm wavelength.

6. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 1, wherein said fixing step is accomplished using ethanol.

7. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 1, wherein said detection is accomplished by passing said cells through a flow cytometer.

8. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 1, wherein said detection is accomplished by means of a fluorescence microscope.

9. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 1, wherein said marking step comprises labeling said photolysis-generated termini of said DNA within said cells with a deoxynucleotide conjugated with a fluorochrome using an exogenous enzyme to catalyze the labeling reaction.

10. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 9, wherein said deoxynucleotide is deoxyuridine triphosphate.

11. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 9, wherein said exogenous enzyme is selected from the group consisting of terminal deoxynucleotidyl transferase and DNA polymerase.

12. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 1, wherein said marking step further comprises the steps of:

- (a) labeling said photolysis-generated termini of said DNA within said cells with a deoxynucleotide conjugated with a first agent using an exogenous enzyme to catalyze the labeling reaction; and
- (b) thereafter incubating said cells with a second agent coupled to a fluorochrome, said agent having an affinity for said first agent and binding thereto.

13. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 12, wherein said deoxynucleotide is deoxyuridine triphosphate.

14. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 12, wherein said exogenous enzyme is selected from the group consisting of terminal deoxynucleotidyl transferase and DNA polymerase.

15. A method for detecting halogenated precursors incorporated into DNA, comprising the steps of:

- (a) incorporating a halogenated precursor into DNA within biological entities;
- (b) exposing said biological entities to ultraviolet light to induce photolysis of said DNA within said biological entities at the sites of said precursor incorporation;
- (c) isolating said DNA from said biological entities;
- (d) analyzing said isolated DNA;
- (e) marking the photolysis-generated termini of said analyzed DNA with a fluorescent label; and
- (f) detecting said fluorescent-labeled DNA.

16. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 15, wherein said incorporating step is accomplished by exposing said biological entities in vitro to said halogenated precursor.

17. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 15, wherein said biological entities are selected from

the group consisting of cells, bacteria, and viruses.

18. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 15, wherein said halogenated precursor is a thymidine base analog selected from the group consisting of 5-bromo-2-deoxyuridine, 5-iodo-2-deoxyuridine, 5-fluoro-2-deoxyuridine, and 5-chloro-2-deoxyuridine.

19. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 15, wherein said analyzing step comprises a gel electrophoresis method.

20. A method for detecting halogenated precursors incorporated into DNA as recited in Claim 15, wherein said analyzing step comprises a blotting method.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/06696

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/00, 1/02, 1/68; G01N 21/75

US CL : 435/4, 5, 6, 29; 436/124, 164, 172

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/4, 5, 6, 29; 436/124, 164, 172

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS, EMBASE, MEDLINE, DERWENT

search terms: halogen?, bromo?, iodo?, chloro? fluoro?, DNA, nucleic acid?, photolys?

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category*       | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                                                                             | Relevant to claim No.              |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| X<br>-----<br>Y | Experimental Cell Research, Volume 174, issued 1988, W. Beisker et al, "Measurement of the Kinetics of DNA Repair Synthesis After UV Irradiation Using Immunochemical Staining of Incorporated 5-Bromo-2'-Deoxyuridine and Flow Cytometry", pages 156-167, see page 157, lines 16-54 through page 158, lines 1-29; page 159, lines 11-12 through page 160, lines 1-9; and page 165, lines 3-7. | 1-2, 4, 6-7<br>-----<br>3, 5, 8-20 |
| Y               | US, A, 5,053,336 (VANDERLAAN ET AL) 01 OCTOBER 1991, see column 1, lines 37-42; column 2, lines 39-58; column 3, lines 25-45; and column 9, lines 64-66.                                                                                                                                                                                                                                       | 3, 8                               |

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

|       |                                                                                                                                                                     |     |                                                                                                                                                                                                                                              |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| * "A" | Special categories of cited documents:<br>document defining the general state of the art which is not considered to be of particular relevance                      | "T" | later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention                                              |
| "E"   | earlier document published on or after the international filing date                                                                                                | "X" | document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                                                                     |
| "L"   | document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" | document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O"   | document referring to an oral disclosure, use, exhibition or other means                                                                                            | "&" | document member of the same patent family                                                                                                                                                                                                    |
| "P"   | document published prior to the international filing date but later than the priority date claimed                                                                  |     |                                                                                                                                                                                                                                              |

Date of the actual completion of the international search

27 JULY 1995

Date of mailing of the international search report

03 AUG 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

NANCY J. DEGEN

Telephone No. (703) 308-0196



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/06696

| C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT |                                                                                                                                                                                                                                                                                                                                     |                       |
|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Category*                                             | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                                                                                                  | Relevant to claim No. |
| Y                                                     | Biochemical Pharmacology, Volume 36, Number 20, issued 1987, M. L. Zucker et al, "Effect of Incorporation of 5-Iodo-2'-Deoxyuridine into HSV-1 DNA on Viron Sensitivity to Ultraviolet Light", pages 3471-3476, see page 3471, column 1, lines 1-13 and column 2, lines 7-10; and page 3472, column 1, lines 15-23 and lines 32-47. | 5, 9-20               |
| Y                                                     | US, A, 5,084,378 (CRISSMAN ET AL) 28 JANUARY 1992, see the abstract, lines 1-19 and column 3, lines 25-39.                                                                                                                                                                                                                          | 9-14, 16-20           |
| Y                                                     | Biochimica et Biophysica Acta, Volume 335, issued 1974, B. W. Glickman, "The Role of DNA Polymerase I in Pyrimidine Dimer Excision and Repair Replication in Eschericia coli K12 Following Ultraviolet Irradiation", pages 115-122, see page 115, lines 1-11 through page 116, lines 1-4.                                           | 9-14, 16-20           |
| Y                                                     | Journal of Molecular Biology, Volume 98, issued 1975, E. M. Southern, "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis", pages 503-517, see page 503, lines 1-20.                                                                                                                              | 9-14, 16-20           |

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)